Patient characteristics
Cancer
ONCOLOGY, VIRUS, EPSTEIN, CANCER
In stage 1 of the trial, among the seven participating patients, three patients achieved an OR. Therefore, another 16 patients were recruited in the second phase. According to the assumed 10% loss to follow-up, finally, 26 eligible patients were registered between 14 January 2021 and 15 September 2021 ((ITT and safety set; Trial profile.Baseline Characteristics of the patients (n = 26).Data are shown as the median (interquartile range (IQR)) or n (%). AJCC = American Joint Committee on Cancer. ECOG = Eastern Cooperative Oncology Group. EBV=Epstein–Barr virus. PD-L1= Program death-ligand 1. VEGFR-2=Vascular Endothelial Growth Factor Receptor-2.